Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Stopped Lack of funding.
Conditions
- Chronic Myeloproliferative Disorders
- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Lymphoproliferative Disorder
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Neoplasms
Interventions
- BIOLOGICAL: anti-thymocyte globulin
- BIOLOGICAL: rituximab
- DRUG: sirolimus
- DRUG: tacrolimus
- OTHER: laboratory biomarker analysis
- PROCEDURE: allogeneic hematopoietic stem cell transplantation
- PROCEDURE: management of therapy complications
- PROCEDURE: peripheral blood stem cell transplantation
Sponsor
Barbara Ann Karmanos Cancer Institute
Collaborators